NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Zacks.com on MSN3d
How to Play SRPT Stock After Patient Death Post DMD Therapy InfusionWe advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...
Wednesday’s 10 Top Performers. In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) ...
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...
Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...
Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price traded down 4% during trading on Thursday after ...
9don MSN
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback